ABSTRACT

Personalized Medicine is a revolutionary healthcare approach, tailors medical treatments to individual patients based on their unique characteristics. This article aims to explores the evolving landscape of Personalized Medicine clinical trials, with over 300,000 global clinical trials evaluating drug efficacy, safety, and treatments. Personalized Medicine has gained significant traction, particularly in cancer studies. The global market for Personalized Medicine reached a noteworthy USD 538.93 billion in 2022, with a projected compound annual growth rate (CAGR) of 7.20% from 2020 to 2030. Regulatory directives in the USA and Europe encompass multifaceted processes, including directives of registration process, reflecting the intricate nature of PM regulatory landscapes. In this article it covers compilation of required documents for clinical trials of Personalized medicines for quick referencing in USA & Europe. Personalized Medicine clinical trials hold immense potential for the future of healthcare, as technology advances will further drive the development of tailored treatments. It calls on readers to stay updated with this rapidly evolving field, as personalized medicine promises a brighter and healthier future for patients worldwide. Keywords: Personalized Medicine, Clinical trial, Study design, Compound annual growth rate (CAGR)
Publication date: 01/02/2025

https://ijbpas.com/pdf/2025/February/MS_IJBPAS_2025_8718.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2025/14.2.8718